Our goal is to solve all diseases by leveraging AI to transform our understanding of biology and chemistry, enabling us to manipulate and craft solutions effectively.

The first generation of AI applications in drug design often focused on local models, but our approach is to build a more comprehensive system that can generalize across various tasks, as demonstrated by AlphaFold 3, which allows us to create models that generalize across chemistry and target space, enabling application to any protein or small molecule without needing fine-tuning.

In the future, the pharmaceutical industry will integrate AI into drug design, making it an essential tool for biology and chemistry.

By 2025, we will be able to design full antibodies and enzymes through advanced AI models, revolutionizing drug development.

We aim to create technologies and platform capabilities that are broadly useful, enabling new mechanistic insights and potentially curing diseases.

Our internal drug design projects focus on immunology and oncology, and we've made significant progress using advanced models.

AI has the potential to improve diagnosis and treatment in healthcare, moving beyond just drug discovery.

Building a diverse team of experts in AI, chemistry, and biology is essential for questioning traditional approaches and fostering innovation in drug design.

The ambition at Isomorphic Labs is to develop a drug design engine that can continuously adapt and apply to new challenges across different diseases, fundamentally changing drug discovery.